Triumeq is owned by Viiv Hlthcare.
Triumeq contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.
Triumeq has a total of 2 drug patents out of which 0 drug patents have expired.
Triumeq was authorised for market use on 22 August, 2014.
Triumeq is available in tablet;oral dosage forms.
The generics of Triumeq are possible to be released after 08 December, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8129385||VIIV HLTHCARE||Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness|| |
(4 years from now)
|US9242986||VIIV HLTHCARE||Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates|| |
(6 years from now)
Market Authorisation Date: 22 August, 2014
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic